Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. / Møller, Holger Jon; K. Moestrup, Søren; Weis, Nina Margrethe; Wejse, Christian; Nielsen, Henrik; Stenvang Pedersen, Svend; Attermann, Jørn; Nexø, Ebba; Kronborg, Gitte; Weis, Nina Margrethe.

I: Critical Care Medicine, Bind 34, Nr. 10, 2006, s. 2561-6.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Møller, HJ, K. Moestrup, S, Weis, NM, Wejse, C, Nielsen, H, Stenvang Pedersen, S, Attermann, J, Nexø, E, Kronborg, G & Weis, NM 2006, 'Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163', Critical Care Medicine, bind 34, nr. 10, s. 2561-6. https://doi.org/10.1097/01.CCM.0000239120.32490.AB

APA

Møller, H. J., K. Moestrup, S., Weis, N. M., Wejse, C., Nielsen, H., Stenvang Pedersen, S., Attermann, J., Nexø, E., Kronborg, G., & Weis, N. M. (2006). Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Critical Care Medicine, 34(10), 2561-6. https://doi.org/10.1097/01.CCM.0000239120.32490.AB

Vancouver

Møller HJ, K. Moestrup S, Weis NM, Wejse C, Nielsen H, Stenvang Pedersen S o.a. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Critical Care Medicine. 2006;34(10):2561-6. https://doi.org/10.1097/01.CCM.0000239120.32490.AB

Author

Møller, Holger Jon ; K. Moestrup, Søren ; Weis, Nina Margrethe ; Wejse, Christian ; Nielsen, Henrik ; Stenvang Pedersen, Svend ; Attermann, Jørn ; Nexø, Ebba ; Kronborg, Gitte ; Weis, Nina Margrethe. / Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. I: Critical Care Medicine. 2006 ; Bind 34, Nr. 10. s. 2561-6.

Bibtex

@article{4f97f75ec9a9491bad75a3e73fa69e0b,
title = "Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163",
abstract = "OBJECTIVE: Soluble CD163 (sCD163) is a new macrophage-specific serum marker. This study investigated sCD163 and other markers of macrophage activation (neopterin, ferritin, transcobalamin, and soluble urokinase plasminogen activator receptor [suPAR]) as prognostic factors in patients with pneumococcal bacteremia. DESIGN: Observational cohort study. SETTING: Five university hospitals in Denmark. PATIENTS: A total of 133 patients with Streptococcus pneumoniae bacteremia (positive blood culture) and 133 age- and gender-matched controls. INTERVENTIONS: Samples were collected for biochemical analyses at the time of first positive blood culture. MEASUREMENTS AND MAIN RESULTS: sCD163 was highly correlated with other macrophage markers and was significantly elevated (median [25-75 percentiles], 4.6 mg/L [2.8-8.9]) compared with healthy controls (2.7 mg/L [2.1-3.3], p < .0001). Increased levels were observed in patients who needed intensive care (hemodialysis, p = .0011; hypotension, p = .0014; mechanical ventilation, p = .0019). Significantly lower levels of sCD163, ferritin, transcobalamin, and suPAR (but not C-reactive protein) were measured in patients > or =75 yrs. In patients <75 yrs, all macrophage markers were increased in patients who died from their infection compared with survivors, whereas no change was observed in any of the markers in the very old age. At cutoff levels of 9.5 mg/L (sCD163) and 1650 nmol/L (C-reactive protein), the relative risk for fatal outcome in patients <75 yrs was 10.1 (95% confidence interval 3.4-31.0) and 7.0 (95% confidence interval 2.4-21.6) for sCD163 and C-reactive protein, respectively. In a multivariate logistic regression model for patients <75 yrs, ferritin, transcobalamin, neopterin, and suPAR contained no significant information on the probability of survival when sCD163 and CRP were known (p = .25). CONCLUSIONS: Macrophage marker response in pneumococcal bacteremia was compromised in old age. In patients <75 yrs old, sCD163 was superior to other markers, including C-reactive protein, in predicting fatal disease outcome.",
author = "M{\o}ller, {Holger Jon} and {K. Moestrup}, S{\o}ren and Weis, {Nina Margrethe} and Christian Wejse and Henrik Nielsen and {Stenvang Pedersen}, Svend and J{\o}rn Attermann and Ebba Nex{\o} and Gitte Kronborg and Weis, {Nina Margrethe}",
year = "2006",
doi = "http://dx.doi.org/10.1097/01.CCM.0000239120.32490.AB",
language = "English",
volume = "34",
pages = "2561--6",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams & Wilkins",
number = "10",

}

RIS

TY - JOUR

T1 - Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163

AU - Møller, Holger Jon

AU - K. Moestrup, Søren

AU - Weis, Nina Margrethe

AU - Wejse, Christian

AU - Nielsen, Henrik

AU - Stenvang Pedersen, Svend

AU - Attermann, Jørn

AU - Nexø, Ebba

AU - Kronborg, Gitte

AU - Weis, Nina Margrethe

PY - 2006

Y1 - 2006

N2 - OBJECTIVE: Soluble CD163 (sCD163) is a new macrophage-specific serum marker. This study investigated sCD163 and other markers of macrophage activation (neopterin, ferritin, transcobalamin, and soluble urokinase plasminogen activator receptor [suPAR]) as prognostic factors in patients with pneumococcal bacteremia. DESIGN: Observational cohort study. SETTING: Five university hospitals in Denmark. PATIENTS: A total of 133 patients with Streptococcus pneumoniae bacteremia (positive blood culture) and 133 age- and gender-matched controls. INTERVENTIONS: Samples were collected for biochemical analyses at the time of first positive blood culture. MEASUREMENTS AND MAIN RESULTS: sCD163 was highly correlated with other macrophage markers and was significantly elevated (median [25-75 percentiles], 4.6 mg/L [2.8-8.9]) compared with healthy controls (2.7 mg/L [2.1-3.3], p < .0001). Increased levels were observed in patients who needed intensive care (hemodialysis, p = .0011; hypotension, p = .0014; mechanical ventilation, p = .0019). Significantly lower levels of sCD163, ferritin, transcobalamin, and suPAR (but not C-reactive protein) were measured in patients > or =75 yrs. In patients <75 yrs, all macrophage markers were increased in patients who died from their infection compared with survivors, whereas no change was observed in any of the markers in the very old age. At cutoff levels of 9.5 mg/L (sCD163) and 1650 nmol/L (C-reactive protein), the relative risk for fatal outcome in patients <75 yrs was 10.1 (95% confidence interval 3.4-31.0) and 7.0 (95% confidence interval 2.4-21.6) for sCD163 and C-reactive protein, respectively. In a multivariate logistic regression model for patients <75 yrs, ferritin, transcobalamin, neopterin, and suPAR contained no significant information on the probability of survival when sCD163 and CRP were known (p = .25). CONCLUSIONS: Macrophage marker response in pneumococcal bacteremia was compromised in old age. In patients <75 yrs old, sCD163 was superior to other markers, including C-reactive protein, in predicting fatal disease outcome.

AB - OBJECTIVE: Soluble CD163 (sCD163) is a new macrophage-specific serum marker. This study investigated sCD163 and other markers of macrophage activation (neopterin, ferritin, transcobalamin, and soluble urokinase plasminogen activator receptor [suPAR]) as prognostic factors in patients with pneumococcal bacteremia. DESIGN: Observational cohort study. SETTING: Five university hospitals in Denmark. PATIENTS: A total of 133 patients with Streptococcus pneumoniae bacteremia (positive blood culture) and 133 age- and gender-matched controls. INTERVENTIONS: Samples were collected for biochemical analyses at the time of first positive blood culture. MEASUREMENTS AND MAIN RESULTS: sCD163 was highly correlated with other macrophage markers and was significantly elevated (median [25-75 percentiles], 4.6 mg/L [2.8-8.9]) compared with healthy controls (2.7 mg/L [2.1-3.3], p < .0001). Increased levels were observed in patients who needed intensive care (hemodialysis, p = .0011; hypotension, p = .0014; mechanical ventilation, p = .0019). Significantly lower levels of sCD163, ferritin, transcobalamin, and suPAR (but not C-reactive protein) were measured in patients > or =75 yrs. In patients <75 yrs, all macrophage markers were increased in patients who died from their infection compared with survivors, whereas no change was observed in any of the markers in the very old age. At cutoff levels of 9.5 mg/L (sCD163) and 1650 nmol/L (C-reactive protein), the relative risk for fatal outcome in patients <75 yrs was 10.1 (95% confidence interval 3.4-31.0) and 7.0 (95% confidence interval 2.4-21.6) for sCD163 and C-reactive protein, respectively. In a multivariate logistic regression model for patients <75 yrs, ferritin, transcobalamin, neopterin, and suPAR contained no significant information on the probability of survival when sCD163 and CRP were known (p = .25). CONCLUSIONS: Macrophage marker response in pneumococcal bacteremia was compromised in old age. In patients <75 yrs old, sCD163 was superior to other markers, including C-reactive protein, in predicting fatal disease outcome.

U2 - http://dx.doi.org/10.1097/01.CCM.0000239120.32490.AB

DO - http://dx.doi.org/10.1097/01.CCM.0000239120.32490.AB

M3 - Journal article

VL - 34

SP - 2561

EP - 2566

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 10

ER -

ID: 34099186